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Inﬂuenza  is  a contagious  respiratory  disease  caused  by  an inﬂuenza  virus.  Due  to  continuous  antigenic
drift  of  seasonal  inﬂuenza  viruses,  inﬂuenza  vaccines  need  to be adjusted  before  every inﬂuenza  season.
This  allows  annual  vaccination  with  multivalent  seasonal  inﬂuenza  vaccines,  recommended  especially
for  high-risk  groups.  There  is  a need  for a seasonal  inﬂuenza  vaccine  that  induces  broader  and  longer
lasting  protection  upon  easy  administration.  EndocineTM is  a lipid-based  mucosal  adjuvant  composed  of
endogenous  lipids  found  ubiquitously  in  the human  body.  Intranasal  administration  of  inﬂuenza  antigens
mixed  with  this  adjuvant  has  been  shown  to induce  local  and  systemic  immunity  as  well  as  protective
efﬁcacy  against  homologous  inﬂuenza  virus  challenge  in mice.  Here  we  used  ferrets,  an  established  ani-
mal  model  for human  inﬂuenza  virus  infections,  to  further  investigate  the  potential  of  EndocineTM as  an
adjuvant.  Intranasal  administration  of  inactivated  pandemic  H1N1/California/2009  split  antigen  or  whole
virus  antigen  mixed  with  EndocineTM induced  high  levels  of serum  hemagglutination  inhibition  (HI) and
virus  neutralization  (VN)  antibody  titers  that  were  also  cross  reactive  against  distant  swine  viruses  of
the same  subtype.  HI and  VN antibody  titers  were  already  demonstrated  after  a single  nasal  immu-
nization.  Upon  intratracheal  challenge  with  a  homologous  challenge  virus  (inﬂuenza  virus  H1N1/The
Netherlands/602/2009)  immunized  ferrets  were  fully  protected  from  virus  replication  in the  lungs  and
largely  protected  against  body  weight  loss,  virus replication  in  the  upper  respiratory  tract  and  patholog-
ical  changes  in  the  respiratory  tract.  EndocineTM formulated  vaccines  containing  split  antigen  induced
higher  HI  and  VN  antibody  responses  and  better  protection  from  body  weight  loss  and  virus  shedding  in
the  upper  respiratory  tract  than  the  EndocineTM formulated  vaccine  containing  whole  virus  antigen.
©  2014  The  Authors.  Published  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND. Introduction
Inﬂuenza A viruses cause annual seasonal epidemics, sporadic
vian inﬂuenza virus infections and inﬂuenza pandemics such as
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264-410X/© 2014 The Authors. Published by Elsevier Ltd. This is an open access article unlicense  (http://creativecommons.org/licenses/by-nc-nd/3.0/).
the H1N1 pandemic virus of 2009–2010 [1]. Seasonal inﬂuenza
A virus infections cause substantial mortality and morbidity, par-
ticularly in high risk groups, such as children younger than age
5, elderly, people with certain chronic medical conditions and
immune-compromised individuals [2]. Active immunization is the
most cost effective way  of limiting inﬂuenza related morbidity
and mortality. Current split-virion or subunit seasonal inﬂuenza
vaccines, of which hemagglutinin (HA) is considered the major
immunogenic component, are effective against circulating homol-
ogous virus strains [3]. Antigenic drift caused by mutations in the
HA, necessitates regular updates of the vaccine composition. Fur-
thermore, more pathogenic viruses such as the newly emerged
pandemic H1N1 virus of 2009 (pH1N1/09) for which among others,
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
3 ccine 
r
n
c
s
i
r
s
b
b
t
f
o
u
f
T
l
u
t
s
d
[
g
a
b
i
t
c
i
i
w
u
a
w
n
a
o
t
i
[
o
m
r
w
c
p
j
h
i
v
s
s
o
i
t
m
a
i
f
m
r
v
i308 A.-K. Maltais et al. / Va
elatively young people were at an increased risk, highlight the
eed for improved inﬂuenza vaccines that induce better, more
ross-protective, and longer lasting immunity than the current sea-
onal vaccines do.
Vaccines administered parenterally induce effective systemic
mmune responses, but only limited local immunity in the respi-
atory tract. Locally produced speciﬁc antibodies, in particular
ecretory IgA (S-IgA) can provide immunity via their unique capa-
ility to neutralize a pathogen before it even passes the mucosal
arrier [4,5]. Moreover S-IgA antibodies have been demonstrated
o contribute to the establishment of increased cross-protection
rom inﬂuenza [6]. Nasal administration of vaccine has the potential
f establishing mucosal immune responses at the ﬁrst site of nat-
ral infection [7]. In addition, nasal administration using a needle
ree delivery system is non-invasive, simply accessible and painless.
he currently licensed nasally administered inﬂuenza vaccines are
ive attenuated inﬂuenza vaccines (LAIV). The LAIV vaccine man-
factured by Medimmune, sold under the trade name FluMist in
he US and Fluenz in Europe, has proven to be effective against
easonal infection and to provide better cross-protection against
rifted inﬂuenza virus strains than the non-live seasonal vaccines
8–10]. However, the use of LAIV is currently restricted to the age
roup of 2 to 59 years, thus excluding children below age 2 as well
s the elderly, both populations classiﬁed as major high risk groups
y the WHO  [2]. Therefore, nasal administration of an inactivated
nﬂuenza vaccine that would be safe and protective through sys-
emic and mucosal immunity, would be an attractive alternative to
urrently used inﬂuenza vaccines.
Appropriate adjuvants or carrier systems have shown to be
ndispensable to ensure effective stimulation of the mucosal
mmune system when non-replicating split or subunit antigens
ere used [11]. A mucosal adjuvant would ideally increase the
ptake of the antigen through the mucus and mucous membrane
nd reduce the required antigen dose while eliciting mucosal as
ell as systemic immunity. Moreover, the adjuvant should ideally
ot cause adverse side effects. Concerns about the safety of mucosal
djuvants are real, since the reporting of an increased incidence
f Bell’s palsy syndrome seen after using an intranasally adminis-
ered inactivated inﬂuenza vaccine, adjuvanted with an apparently
nsufﬁciently detoxiﬁed mutant of the E. coli heat labile enterotoxin
12,13]. Nevertheless, research on the design and development
f effective and safe intranasal adjuvants is ongoing and several
ucosal adjuvants which support inﬂuenza immunity are cur-
ently under investigation [14–18].
EndocineTM, an adjuvant system based on endogenous lipids,
as tested in three clinical phase I studies. A nasal diphtheria vac-
ine formulated with EndocineTM (1 or 4%) was  evaluated in a
hase I study in 2002, and was found to be safe and tolerable. Sub-
ects receiving the diphtheria vaccine with 4% EndocineTM had a
igher increase in neutralization titers compared to subjects receiv-
ng unadjuvanted vaccine (unpublished data). An inactivated whole
irus inﬂuenza vaccine and an HIV vaccine, and was shown to be
afe and tolerable in all studies [19,20]. Pre-clinical studies with
plit virion inﬂuenza vaccines showed that EndocineTM, (previ-
usly known as L3B), signiﬁcantly increases both local and systemic
mmune responses after intranasal immunization [21]. Addition of
he adjuvant to a subunit inﬂuenza antigen given intranasally to
ice conferred protection (measured by detection of viral RNA)
gainst homologous virus challenge [22].
To further investigate the potential of EndocineTM to adjuvant
nactivated nasal inﬂuenza vaccines we used the ferret as a model
or inﬂuenza. Ferrets are considered to be the most suitable animal
odel for the different forms of human inﬂuenza and are natu-
ally susceptible to infection with all wildtype human inﬂuenza A
iruses causing clinical changes in ferrets similar to those observed
n humans. Also the pathogenesis and antibody responses observed32 (2014) 3307–3315
in ferrets are quite similar to those in humans [23,24]. Furthermore
ferrets share similarities in lung physiology and airway morphology
with humans [25,26] and the pattern of inﬂuenza virus attachment
and replication in the ferret respiratory tract is largely similar to
that in humans [27].
In the current study the efﬁcacy of nasal EndocineTM adju-
vanted split virion and whole virus pH1N1/09 candidate vaccines
was evaluated using the homologous wildtype H1N1 A/The
Netherlands/602/2009 (wt-pH1N1) virus as a challenge. Humoral,
hemagglutination inhibiting (HI) and virus neutralizing (VN) anti-
body responses against homologous and three distant swine H1N1
viruses were evaluated. Efﬁcacy was  measured by evaluating clin-
ical, virological and pathology parameters. In addition computed
tomography (CT) imaging was  performed as a newly developed
read out parameter of efﬁcacy by quantifying alterations in aerated
lung volumes (ALV) [28,29].
2. Materials and methods
2.1. Vaccines
Vaccine nasal drops: EndocineTM 20 mg/ml  formulated inactiv-
ated H1N1/California/2009 split virion antigen at 5, 15 and 30 g
HA/0.2 ml  and whole virus antigen at 15 g HA/0.2 ml  were pro-
vided by Eurocine Vaccines AB (Stockholm, Sweden). Parenteral
vaccine: Fluarix®, season 2010/2011, also containing inactivated
H1N1/California/2009 (GlaxoSmithKline).
2.2. Ferrets
Healthy female ferrets (Mustela putorius furo: outbred), approx-
imately 12 months of age, with body weights of 760-1210 g and
seronegative for antibodies against circulating inﬂuenza viruses B,
A/H1N1, A/H3N2 and A/pH1N1 as demonstrated by hemaggluti-
nation inhibition (HI) assays were used. Animals were housed in
standard cages, in groups of maximal 8 animals during the pre-
immunization phase and in study groups of 6 animals during the
immunization phase. The study groups were transferred to nega-
tively pressurized glovebox isolator cages on the day of challenge.
During the whole study animals were provided with commer-
cial food pellets and water ad libitum. The experimental protocol
was approved before start of the experiments by an indepen-
dent institutional animal ethics committee according to the Dutch
law.
2.3. Immunization
Five groups of six ferrets received three intranasal immun-
izations (droplets: 100 l in each nostril, using a pipet with
ﬁltertip) under anesthesia with ketamine and domitor at days
0, 21 and 42. Groups 3, 4 and 5 were intranasally immunized
with 200 l EndocineTM formulated H1N1/California/2009 split
antigen containing 5, 15 and 30 g HA, respectively. Group 6
was intranasally immunized with 200 l EndocineTM formulated
H1N1/California/2009 whole virus antigen containing 15 g HA.
Control group 1 received 200 l of saline intranasally. One group
of six ferrets (group 2) received two  subcutaneous immunizations
(days 21 and 42 using 25Gx5/8” needles) with 0.5 ml  Fluarix®,
season 2010/2011, a non-adjuvanted trivalent inﬂuenza vaccine
(TIV) that also contains the pH1N1 (15 g HA) component. Blood
samples for serum preparation were collected prior immunization
on days 0, 21 and 42 and before challenge on study days 64 and
70.
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.4. Challenge with wild type H1N1 A/The Netherlands/602/09
irus
Four weeks after the last immunization (day 70), all ferrets were
hallenged with wild-type inﬂuenza A/Netherlands/602/2009 (wt-
H1N1) virus as previously described [30]. Brieﬂy, 106 50% tissue
ulture infective doses (TCID50) of wt-pH1N1 virus was diluted
n 3 ml  of PBS and administered via the intratracheal route under
nesthesia with a cocktail of ketamine and domitor.
.5. Procedures and sample collection
Several procedures were performed on the ferrets over the
ourse of the experiment. For implantation of temperature sensors,
mmunizations, viral challenge and computed tomography (CT)
maging the animals were anesthetized with a cocktail of ketamine
4-8 mg/kg: i.m.; Alfasan, Woerden, The Netherlands) and domi-
or (0.1 mg/kg: i.m.; Orion Pharma, Espoo, Finland). For sampling
blood, swabs and nasal washes) and euthanasia by exsanguina-
ion, the animals were anesthetized with ketamin. Two  weeks prior
o the start of the experiment, a temperature logger (DST micro-
 ultrasmall temperature logger; Star-Oddi, Reykjavik, Iceland)
as placed in the peritoneal cavity of the ferrets. This device
ecorded body temperature of the animals every 10 min. Ferrets
ere weighed prior to each immunization (days 0, 21 and 42) and
n the days of challenge and euthanasia (days 70 and 74). Animals
f groups 1, 2 and 4 were monitored by CT imaging on days 64, 71,
2, 73 and 74. Blood samples were collected prior to the immuniza-
ion on days 0, 21 and 42, on day 64 and before challenge on day
0. Nose and throat swabs were collected prior challenge on day
0 and on each day after challenge.
.6. HI and VN antibody assays
Serum samples, collected on days 0, 21, 42, 64 and 70 were
tored at −80 ◦C until analysis. Sera were tested in HI and
N assays as previously described [31,32] against H1N1 A/The
etherlands/602/2009 virus and the two distant swine viruses
1N1 A/Swine/Ned/25/80 and H1N1 A/Swine/Italy/14432/76. In
ddition HI serum antibody titers against the distant virus
1N1 A/New Jersey/08/76 were determined (VN assay for this
train was not possible due to insufﬁcient amount of serum).
he antigenic distance from H1N1 A/Netherlands/602/2009 to
/swine Netherlands/25/1980, A/swine/Italy/14432/76 and A/New
ersey/08/1976 is 2.3, 4.4 and 7.7 antigenic units, respectively
unpublished data), on basis of antigenic cartography which allows
o quantify HI assay data made with ferret post-infection sera,
here 1 antigenic unit corresponds with a 2-fold difference in HI
ssay titer [33].
.7. Virus replication in the upper and lower respiratory tract
On days 0, 1, 2, 3 and 4 after challenge, nose and throat swabs
ere taken from the animals under anesthesia. Four days after
hallenge, the ferrets were euthanized by exsanguination under
nesthesia after which full-body gross-pathology was  performed
nd tissues were collected. Samples of the right nose turbinate
nd of all lobes of the right lung and the accessory lobe were
ollected and stored at −80 ◦C until further processing. Turbinate
nd lung samples were weighed and subsequently homogenized
ith a FastPrep-24 (MP  Biomedicals, Eindhoven, The Netherlands)
n Hank’s balanced salt solution containing 0.5% lactalbumin, 10%
lycerol, 200 U/ml penicillin, 200 g/ml streptomycin, 100 U/ml
olymyxin B sulfate, 250 g/ml gentamycin, and 50 U/ml nys-
atin (ICN Pharmaceuticals, Zoetermeer, The Netherlands) and
entrifuged brieﬂy before dilution.32 (2014) 3307–3315 3309
After collection, nose and throat swabs were stored at −80 ◦C in
the same medium as used for the processing of the tissue samples.
Quadruplicate 10-fold serial dilutions of lung and swab super-
natants were used to determine the virus titers in conﬂuent layers
of MDCK cells as described previously [34].
2.8. Gross-pathology and histopathology
The animals were necropsied according to a standard protocol,
as previously described [35]. In short, the trachea was  clamped
off so that the lungs would not deﬂate upon opening the pleural
cavity allowing for an accurate visual quantiﬁcation of the areas
of affected lung parenchyma. Samples for histological examina-
tion of the left lung were taken and stored in 10% neutral-buffered
formalin (after slow infusion with formalin), embedded in paraf-
ﬁn, sectioned at 4 m,  and stained with hematoxylin and eosin
(HE) for examination by light microscopy. Samples were taken
in a standardized way, not guided by changes observed in the
gross pathology. Semi-quantitative assessment of inﬂuenza virus-
associated inﬂammation in the lung was performed as described
previously (Table 1) [30]. All slides were examined without knowl-
edge of the identity or treatment of the animals.
2.9. Computed tomography (CT)
A dual-source ultrafast CT system (Somatom Deﬁnition Flash;
Siemens Healthcare) was used (temporal resolution: 0.075 s, spatial
resolution: 0.33 mm,  table speed: 458 mm/s; ferret thorax acqui-
sition times ≈0.22 s; enables accurate scanning of living ferrets
without the necessity of breath-holding, respiratory gating, or elec-
trocardiogram (ECG)-triggering) as previously described [28,29].
Brieﬂy, all animals of group 1 (saline; infection control), group 2
(TIV; parenteral control) and of group 4 (nasal EndocineTM formu-
lated split antigen, 15 g HA) were scanned 6 days prior to virus
inoculation (day 64) to deﬁne the uninfected baseline status of the
respiratory system, and after challenge on 1, 2, 3 and 4 days post
inoculation (dpi). During in vivo scanning the anesthetized ferrets
were positioned in dorsal recumbency in a perspex biosafety con-
tainer of approximately 8.3 l capacity that was custom designed
and built (Tecnilab-BMI). The post-infectious reductions in aerated
lung volumes were measured from 3-dimensional CT reconstructs
using lower and upper thresholds in substance densities of −870
to −430 Hounsﬁeld units (HU).
2.10. Statistical analysis
Differences between the groups immunized with the
EndocineTM adjuvanted H1N1/California/2009 vaccine prepa-
rations (groups 3–6) were analyzed statistically using the
Kruskal–Wallis test. Differences between the sham (saline)
immunized control group and the immunized groups were
statistically analyzed using the two-tailed Mann–Whitney test.
3. Results
3.1. Immunogenicity of nasal EndocineTM adjuvanted versus
parenteral non-adjuvanted inactivated pH1N1/09 vaccines
3.1.1. HI antibody responses
One intranasal immunization with EndocineTM adjuvanted split,
or whole virus antigen induced high homologous HI antibody titers:
in all ferrets of groups 3 and 5 (5 and 30 g HA split antigen; titers
160–1120 and 400–3200, respectively) and in 5 out of 6 ferrets
of groups 4 and 6 (15 g HA split and whole virus antigen at;
titers ≤5–5760 and 5–1280, respectively). A second immunization
3310
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Table 1
Semi-quantitative scoring for histopathological parameters on 4 dpi.
Groupa
1 2 3 4 5 6
Histopathology Extent of alveolitis/alveolar damage (score 0–3) 2.08 ± 0.74 (6/6) 1.88 ± 0.54 (6/6) 0.42 ± 0.52 (3/6) 0.08 ± 0.20 (1/6) 0.04 ± 0.10 (1/6) 0.42 ± 0.41 (4/6)
Severity of alveolitis (score 0–3) 2.04 ± 0.68 (6/6) 1.63 ± 0.31 (6/6) 0.50 ± 0.69 (3/6) 0.08 ± 0.20 (1/6) 0.04 ± 0.10 (1/6) 0.46 ± 0.46 (4/6)
Alveolar oedema (% slides positive) 29 ± 29 (4/6) 21 ± 19 (4/6) 4 ± 10 (1/6) 0 ± 0 (0/6) 0 ± 0 (0/6) 8 ± 13 (2/6)
Alveolar hemorrhage (% slides positive) 21 ± 40 (2/6) 17 ± 26 (2/6) 0 ± 0 (0/6) 0 ± 0 (0/6) 0 ± 0 (0/6) 0 ± 0 (0/6)
Type  II pneumocyte hyperplasia (% slide positive) 42 ± 34 (4/6) 46 ± 37 (4/6) 8 ± 20 (1/6) 4 ± 10 (1/6) 0 ± 0 (0/6) 4 ± 10 (1/6)
a Group 1 (control, i.n. saline), group 2 (s.c. TIV), group 3 (i.n. EndocineTM adjuvanted split antigen at 5 g HA), group 4 (i.n. EndocineTM adjuvanted split antigen at 15 g HA), group 5 (i.n. EndocineTM adjuvanted split antigen
at  30 g HA) and group 6 (i.n. EndocineTM adjuvanted inactivated whole virus antigen at 15 g HA).
Histopathology. Semi-quantitative scoring for histopathological parameters on 4 dpi. Extent of alveolitis/alveolar damage, score: 0, 0%; 1, 25%; 2, 25–50%; 3, > 50%; severity of alveolitis, score: no inﬂammatory cells (0); few
inﬂammatory cells (1); moderate numbers of inﬂammatory cells (2); many inﬂammatory cells (3); alveolar oedema, alveolar hemorrhage and type II pneumocyte hyperplasia were scored as positive slides (no = 0, yes = 1); All
histopathology results are presented as average with standard deviation.
Table 2
Efﬁcacy of EndocineTM formulated 2009 H1N1 vaccines in ferrets demonstrated by clinical, virological and gross-pathology parameters.
Groupa
1 2 3 4 5 6
Clinical score
Survival 6/6 5/6 6/6 6/6 6/6 6/6
Fever  1.7 ± 0.6 (6/6) 1.1 ± 0.4 (6/6) 1.3 ± 0.3(6/6) 1.2 ± 0.6(4/5*) 1.1 ± 0.6(6/6) 1.3 ± 0.2(6/6)
Body  weight loss 18.0 ± 4.6 (6/6) 11.5 ± 2.1 (6/6) −2.2 ± 2.6 (1/6) 1.7 ± 1.5 (4/6) 2.7 ± 3.3 (4/6) 4.7 ± 3.1 (6/6)
Virology
Lung  virus load [log10TCID50/g] 5.7 ± 0.5 (6/6) 5.5 ± 0.9 (6/6) ≤1.5 (0/6) ≤1.4 (0/6) ≤1.3 (0/6) ≤1.3 (0/6)
Turbinates virus load [log10TCID50/g] 7.2 ± 2.4 (6/6) 6.9 ± 1.5 (6/6) ≤1.9 (0/6) ≤1.7 (0/6) ≤1.7 (0/6) 4.1 ± 2.7 (3/6)
Virus  shedding in nasal swabs 2.6 (5/6) 1.2 (4/6) 0.058 (1/6) 0.0 (0/6) 0.0 (0/6) 1.4 (3/6)
Virus  shedding in throat swabs 10 (6/6) 10 (6/6) 0.0 (1/6) 0.14 (1/6) 0.0 (1/6) 4.2 (5/6)
Gross  pathology
Affected lung tissue [%] 50 ± 25 (6/6) 37 ± 21 (6/6) 8 ± 4 (5/6) 7 ± 5 (4/6) 7 ± 5 (4/6) 8 ± 4 (5/6)
Relative  lung weight 1.5 ± 0.5 1.3 ± 0.1 0.8 ± 0.1 0.8 ± 0.1 0.8 ± 0.2 0.9 ± 0.1
a Group 1 (control, i.n. saline), group 2 (s.c. TIV), group 3 (i.n. EndocineTM adjuvanted split antigen at 5 g HA), group 4 (i.n. EndocineTM adjuvanted split antigen at 15 g HA), group 5 (i.n. EndocineTM adjuvanted split antigen
at  30 g HA) and group 6 (i.n. EndocineTM adjuvanted inactivated whole virus antigen at 15 g HA).
Clinical Scores.  Survival, number of animals that survived up to 4 dpi; fever (0C), maximum temperature increase presented as average with standard deviation, number of animals in which fever was  observed in parentheses, (*),
body  temperature of 1 animal in group 4 was  not available due to malfunction of the recorder; % body weight loss between 0 and 4 dpi presented as average with standard deviation, number of animals with body weight loss in
parentheses. Virology. Virus shedding in nose and throat swab samples, area under the curve (AUC) for titration results 1–4 dpi, number of animals showing 1 or more virus positive swab in parentheses; virus load in lung and
turbinates (log10TCID50/g) on 4 dpi presented as average with standard deviation, or the lower limit of detection in case all animals in the group were virus negative, number of animals with lung/turbinate virus in parentheses.
Gross  pathology. % of estimated affected lung parenchyma by visual examination during necropsy on 4 dpi presented as average with standard deviation, number of animals with affected lung in parentheses; lung/body weight
ratio  (×102) on 4 dpi presented as average with standard deviation.
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Fig. 1. Development of HI antibody titers against H1N1 A/Ned/602/09 (A),
A/Swine/Ned/25/80 (B), A/Swine/Italy/14432/76 (C) and A/New Jersey/08/76 (D).
Ferrets of group 1, 3–6 were intranasally inoculated by nasal drops on days 0, 21
and  42 and ferrets of group 2 were subcutaneously injected on days 21 and 42. Blue;
group 1 (control, i.n. saline), red; group 2 (s.c. TIV), yellow; group 3 (i.n. EndocineTM
adjuvanted split antigen at 5 g HA), green; group 4 (i.n. EndocineTM adjuvanted
split antigen at 15 g HA), gray; group 5 (i.n. EndocineTM adjuvanted split antigen at
30  g HA) and black; group 6 (i.n. EndocineTM adjuvanted inactivated whole virus
antigen at 15 g HA). Bars represent geometric mean of 6 animals per group withA.-K. Maltais et al. / Va
ncreased HI antibody titers in all ferrets, irrespective of anti-
en and antigen dose (groups 3–6, titers 1120–2560, 1120–5760,
40–3840 and 100–2880, respectively) (Fig. 1A). A third intranasal
mmunization did not substantially boost the HI immune response
urther (groups 3–6, titers 1280–3840, 1920–4480, 1280–3200
nd 160–2560, respectively). The differences in HI antibody titers
etween the 3 split antigen HA doses (groups 3, 4 and 5) were not
igniﬁcant (p > 0.05). However, mean HI antibody titers in group
 (15 g HA split antigen) were signiﬁcantly higher than those in
roup 6 (15 g HA whole virus antigen); p = 0.01 and p = 0.02 after
 and 3 immunizations, respectively.
Cross-reactive HI antibodies were measured against the distant
1N1 viruses A/Swine/Ned/25/80, H1N1 A/Swine/Italy/14432/76
nd H1N1 A/New Jersey/08/76 (Fig. 1B–D, respectively). The high-
st cross-reactive HI antibody titers were measured in group 4
15 g HA split antigen) after 2 immunizations. Cross-reactive HI
ntibody titers were signiﬁcantly higher in group 4 (15 g HA split
ntigen) than in group 6 (15 g HA whole virus antigen) against
1N1 A/Swine/Ned/25/80 and H1N1 A/Swine/Italy/14432/76
iruses (p = 0.0194 and p = 0.0292), but not against H1N1 A/New
ersey/08/76. Of note, the cross-reactive HI antibody proﬁles
gainst the distant H1N1 viruses A/Swine/Italy/14432/76 and
/New Jersey/08/76 after 2 immunizations (serum sample day
2) were generally in agreement with the calculated antigenic
istances that were obtained using post-infection sera. Remark-
bly, only the cross-reactive HI antibody proﬁle against the distant
1N1 virus A/Swine/Ned/25/80 induced in group 4 (15 g HA split
ntigen) was in agreement with the calculated antigenic distance
p = 0.1269) whereas these cross-reactive HI responses in the other
roups were signiﬁcantly lower (p ≤ 0.0245).
Parenteral, non-adjuvanted trivalent inﬂuenza vaccine (TIV)
group 2) displayed relatively limited immunogenicity inducing
fter two immunizations only in one out of the six ferrets a homol-
gous HI antibody titer ≥40 (titer range 13–70; Fig. 1A) and no
ross-reactive HI antibody titers (mean titer <40 (Fig. 1B–D).
.2. VN antibody responses
VN antibody responses closely paralleled those measured in the
I assays. Homologous VN antibody titers were induced after a sin-
le intranasal immunization with EndocineTM adjuvanted split, or
hole virus antigen: In 4 out of 6 ferrets of group 3 (5 g HA split
ntigen; titers ≤8–64), in 5 out of 6 ferrets of group 4 (15 g HA
plit antigen; titers ≤8–724), in all ferrets of group 5 (30 g HA
plit antigen; titers 11–627) and in 2 out of 6 ferrets of group 6
15 g HA whole virus antigen; titers ≤8–64). A second immuniza-
ion increased the VN antibody titers in all ferrets, irrespective of
he antigen and antigen dose (groups 3–6, titers 64–859, 64–8192,
1–3435 and 32–304) (Fig. 2A). A third immunization was  effec-
ive in 5 out of 6 animals in group 3 (titers, 362–2436), 2 out of 6 in
roup 4 (titers, 662–4871), 3 out of 6 in group 5 (titers, 724–4884)
nd in all animals of group 6 (titers, 113–747). The differences in
N antibody titers between the 3 split antigen HA doses (groups
, 4 and 6) were not signiﬁcant (p > 0.05). However, mean VN anti-
ody titers in group 4 (15 g HA split antigen) were signiﬁcantly
igher than in group 6 (15 g HA whole virus antigen); p = 0.03 and
 = 0.01 after 2 and 3 immunizations, respectively.
Measuring VN antibodies against the distant viruses H1N1
/Swine/Ned/25/80 and H1N1 A/Swine/Italy/14432/76 showed the
ighest cross-reactive VN antibody titers in group 4 (15 g HA split
ntigen) after 2 immunizations, but the differences were not signif-
cant (Fig. 2B and C, respectively). Parenteral, non-adjuvanted TIV
group 2) did not induce VN antibody titers (Fig. 2).
95%  CI (GMT ± CI95). See text for statistical analysis of the results. (For interpreta-
tion  of the references to color in this ﬁgure legend, the reader is referred to the web
version of this article.)
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Fig. 2. Development of VN antibody titers against H1N1 A/Ned/602/09 (A),
A/Swine/Ned/25/80 (B) and A/Swine/Italy/14432/76 (C). Ferrets of group 1, 3–6 were
intranasally inoculated by nasal drops on days 0, 21 and 42 and ferrets of group 2
were subcutaneously injected on days 21 and 42. Blue; group 1 (control, i.n. saline),
red; group 2 (s.c. TIV), yellow; group 3 (i.n. EndocineTM adjuvanted split antigen at
5  g HA), green; group 4 (i.n. EndocineTM adjuvanted split antigen at 15 g HA), gray;
group 5 (i.n. EndocineTM adjuvanted split antigen at 30 g HA) and black; group 6
(i.n. EndocineTM adjuvanted inactivated whole virus antigen at 15 g HA). Bars rep-
resent geometric mean of 6 animals per group with 95% CI (GMT ± CI95). NP = not
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terformed. See text for statistical analysis of the results. (For interpretation of the
eferences to color in this ﬁgure legend, the reader is referred to the web version of
his  article.)
.3. Protective efﬁcacy of inactivated nasal EndocineTM
djuvanted versus parenteral non-adjuvanted pH1N1/09 vaccines
gainst a homologous challenge
.3.1. Clinical signs
Challenge with the homologous wt-pH1N1 was performed four
eeks after the last immunization. All ferrets of groups 3–6 (i.n.
ndocineTM adjuvanted pH1N1/09 vaccines) as well as control
roup 1 (i.n. saline) survived the follow-up of 4 days post inoc-
lation (dpi), when they were euthanized. The observation that
ntratracheal infection with 106 TCID50 of wt-pH1N1 was not lethal
n the naïve control ferrets is in accordance with earlier observa-
ions with this virus in ferrets [35,30,36]. However, 1 out of 6 ferrets32 (2014) 3307–3315
of control group 2 (s.c. TIV) was found dead on 4 dpi. Pathology
revealed that this animal suffered from acute extensive pneumo-
nia, which was  the most probable cause of death since no other
lesions were evident at necropsy.
Fever was observed in all groups (Table 2). Ferrets of control
group 1 displayed the highest fever (mean maximum temperature
increase of 1.7 ◦C), but the differences between control group 1 and
the immunized groups (mean maximum temperature increase of
1.1–1.3 ◦C) were not signiﬁcant.
Intranasal immunization with EndocineTM adjuvanted split
antigen prevented body weight loss in 5 out of 6 ferrets of group
3 (5 g HA), 2 out of 6 ferrets of group 4 (15 g HA) and 2 out of
6 ferrets of group 5 (30 g HA) (Table 2). Body weight loss was
most pronounced in control groups 1 (i.n. saline) and 2 (parenteral
TIV) and with a mean body weight loss of 18.0% and 11.5%, respec-
tively, signiﬁcantly higher than in the immunized groups 3 (−2.2%),
4 (1.7%), 5 (2.7%) and 6 (4.7%).
3.4. Virus load in lung and upper respiratory tract
All ferrets of control groups 1 (i.n. saline) and 2 (parenteral
TIV) showed high titers of replication competent virus in lung
(mean titers; 5.7 and 5.5 log10TCID50/gram tissue, respectively)
and nasal turbinates (mean titers: 7.2 and 6.9 log10TCID50/gram
tissue, respectively) (Table 2). Ferrets of groups 3, 4 and 5 (i.n.
EndocineTM adjuvanted split antigen pH1N1/09 vaccines) had no
detectable infectious virus in their lungs and nasal turbinates. Fer-
rets of group 6 (i.n. EndocineTM adjuvanted whole virus at 15 g HA)
had no detectable infectious virus in their lungs and with a mean
titer of 4.1 log10TCID50/gram tissue a signiﬁcantly lower virus titer
in the nasal turbinates as compared to control group 1 (p = 0.02).
Intranasal immunization with EndocineTM adjuvanted
pH1N1/09 vaccines reduced virus titers in swabs taken from
the nose and throat as compared to saline or TIV administration.
Virus loads expressed as area under the curve (AUC) in the time
interval of 1–4 dpi, in nasal and throat swabs are shown in Table 2.
Virus loads in nasal swabs of groups 3, 4 and 5 (i.n. EndocineTM
adjuvanted split antigen at 5, 15 and 30 g HA, respectively), but
not of groups 2 and 6 were signiﬁcant lower than in group 1 (group
1 versus groups 3–5; p ≤ 0.03). Virus loads in throat swabs of group
1 and 2 were comparable and signiﬁcant higher than in groups 3,
4, 5 and 6 (p ≤ 0.03).
3.5. Gross-pathology and histopathology
Reduced virus replication in groups intranasally immunized
with the EndocineTM adjuvanted pH1N1/09 vaccines corresponded
with a reduction in gross-pathological changes of the lungs
(Table 2).
The macroscopic post-mortem lung lesions consisted of focal or
multifocal pulmonary consolidation, characterized by well delin-
eated reddening of the parenchyma. All ferrets in control group
1 (i.n. saline) and group 2 (parenteral TIV) showed affected lung
tissue with a mean percentage of 50% and 37%, respectively, and
corresponded with a mean relative lung weight (RLW) of 1.5
and 1.3, respectively (Table 2). In contrast, lungs in groups 3–6
(i.n. EndocineTM adjuvanted pH1N1/09 vaccines) were much less
affected with mean percentages of affected lung tissue of 7–8%.
The RLWs in these four EndocineTM-vaccinated groups were in line
with these observations (in a close range of 0.8 to 0.9).
The pulmonary consolidation corresponded with an acute
broncho-interstitial pneumonia at microscopic examination. It
was characterized by the presence of inﬂammatory cells (mostly
macrophages and neutrophils) within the lumina and walls of
alveoli, and swelling or loss of lining pneumocytes. In addition pro-
tein rich oedema ﬂuid, ﬁbrin strands and extravasated erythrocytes
A.-K. Maltais et al. / Vaccine 
Fig. 3. Changes in aerated lung volume after infection with H1N1
A/Netherlands/602/2009. Blue; group 1 (control, i.n. saline), red; group 2 (s.c.
TIV),  green; group 4 (i.n. EndocineTM adjuvanted split antigen at 15 g HA).
The aerated lung volume was calculated using lower and upper thresholds in
substance densities of −870 to −430 Hounsﬁeld units (HU) for the analysis of
3D-reconstructions of the lung. The percentage change of aerated lung volume was
calculated using the individual base line aerated lung volumes of day −6 against the
aerated lung volumes of the different days after infection. These data are expressed
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ls  mean ± SEM. Animals were intratracheally challenged with 106 TCID50 H1N1
/The Netherlands/602/2009 on day 0. (For interpretation of the references to color
n  this ﬁgure legend, the reader is referred to the web version of this article.)
n alveolar spaces and type II pneumocyte hyperplasia were gener-
lly observed in the more severe cases of alveolitis. The histological
arameters that were scored are summarized in Table 1. The most
evere alveolar lesions were found in the control groups 1 (i.n.
aline) and 2 (parenteral TIV). All parameters of alveolar lesions
cored lowest in group 5, but in fact the differences between the
roups 3–6 were not signiﬁcant.
.6. Computed tomography (CT)
The development of pulmonary lesions was  investigated by
eans of CT in ferrets of group 1 (i.n. saline), group 2 (s.c. TIV)
nd group 4 (i.n. EndocineTM adjuvanted split antigen at 15 g
A), largely as described previously [29]. Consecutive in vivo imag-
ng with CT scanning showed that ferrets of group 4 were largely
rotected against the appearance of pulmonary ground-glass opac-
ties. Post infection reduction in aerated lung volumes (ALV) were
easured from 3D CT reconstructs using lower and upper thresh-
lds in substance densities of −870 to −430 HU. Ferrets of control
roup 1 showed a temporal signiﬁcant increase in ALV on 1 dpi,
s compared to both immunized groups 2 and 4 (Mann Whitney,
wo-tailed, p = 0.05) (Fig. 3). Subsequently, the ferrets of group 1
howed a decrease of ALV at 2 dpi, which remained low on 3 and
 dpi (group mean ALV ranging from 17.3 to −14.3%). Ferrets of
roup 4 were protected against major alterations in ALV (group
ean ALV ranging from 0.95 to −7.8%), whereas ferrets of group 2
howed an intermediate decrease of ALV (group mean ALV ranging
rom 2.7 to −10.0%).
. Discussion
Nasal inﬂuenza vaccines composed of inactivated pH1N1/09
plit or whole virus antigen mixed with EndocineTM adjuvant
nduced high antibody titers in inﬂuenza naïve ferrets and protec-
ion against homologous challenge. Nasal EndocineTM formulated
nactivated pH1N1/09 inﬂuenza vaccines induced high levels of
erum HI and VN antibodies, which were in the same order of
agnitude as antibody levels found in inﬂuenza naïve ferrets
ntranasally immunized with monovalent H1N1/California/2009
ive attenuated inﬂuenza vaccines (LAIVs) [37–39] or in inﬂuenza32 (2014) 3307–3315 3313
naïve ferrets intramuscularly immunized with AS03 adjuvanted
H1N1/California/2009 split vaccines [39]. The results in control
ferrets parenterally immunized with non-adjuvanted seasonal TIV
were similar to those seen in naïve controls (i.n. saline). The par-
enteral non-adjuvanted seasonal TIV did not induce protective
HI and VN antibody titers in inﬂuenza naïve ferrets, which is
in accordance with the general observation that non-adjuvanted
inactivated inﬂuenza vaccines and in particular split antigen vac-
cines are weakly immunogenic in inﬂuenza naïve ferrets [39–41].
The inﬂuenza naïve ferret model may  be considered a repre-
sentative pre-clinical animal model for inﬂuenza vaccine efﬁcacy
in inﬂuenza naïve individuals. A study on prevalence of antibod-
ies against seasonal inﬂuenza A and B viruses in children in The
Netherlands showed that children between 2 and 3 years of age
have the highest attack rate [42]. In addition it was  shown that
the seroprevalence of antibodies to inﬂuenza viruses was higher
in children 1 to 6 months of age than in children 7 to 12 months
to age, reﬂecting the window of maternal antibodies. During the
time when maternal antibodies are helping protect children against
infections the nasopharyngeal tonsil (adenoid) develops in chil-
dren [43]. The adenoid, which is part of the lymphoid tissue of
Waldeyer’s ring, is active in early childhood up till the time of ado-
lescence, and has been reported to be functionally comparable to
nasal-associated lymphoid tissue (NALT) in rodents [44]. Several
studies have suggested that NALT/Waldeyer’s ring is a mucosal
inductive site for humoral and cellular immune responses in the
upper respiratory tract [45], and that tonsils and adenoids might
function as effector sites of adaptive immunity [46]. Since the ade-
noid is unique to children and strategically placed exposed to both
alimentary and airborne antigens, nasal vaccines have an espe-
cially interesting potential in children. Vaccination of children older
than 6 months against seasonal inﬂuenza is either recommended,
or considered by several public health authorities [47,48]. This is
based on studies, which demonstrate that annual vaccination of
children is beneﬁcial and usually cost-effective [49,47,50]. Children
in the age of 6–24 months who  have not experienced an inﬂuenza
virus infection will most likely beneﬁt from vaccination. Still many
European health authorities are reluctant to include inﬂuenza vac-
cination in their national vaccination programs. Doubts about the
efﬁcacy of available inﬂuenza vaccines most likely plays a substan-
tial role in the decision making progress [51,52]. The possibility
of preventing inﬂuenza in children aged 6–24 months by means
of available vaccines still remains an open question. For children of
this age group LAIVs are not licensed due to an increase in hospital-
ization and wheezing post administration and adjuvanted seasonal
TIVs have not yet been licensed for this age group, because of lack
of adequate safety data [51]. Consequently, there is a continuing
need to design and develop a new generation of broadly protective
and safe vaccines, especially for this age category.
The anionic adjuvant EndocineTM was  developed speciﬁcally to
formulate intranasal vaccines. EndocineTM is composed of endoge-
nous lipids found ubiquitously in the human body and has been
tested successfully in clinical trials with diphtheria, inﬂuenza and
HIV [19–21] (and unpublished data). The results of these trials
showed that EndocineTM is safe and tolerable in humans, and in the
inﬂuenza trial the EndocineTM adjuvanted whole virus vaccine ful-
ﬁlled the EMA/CHMP HAI criteria for a seasonal inﬂuenza vaccine.
Moreover, inﬂuenza-speciﬁc IgA was  measured in nasal swabs and
it was  shown that the EndocineTM adjuvanted vaccine induced a
signiﬁcantly higher fold-increase in nasal IgA compared to the mock
vaccine with EndocineTM alone [19]. In line with these observations,
no adverse effects of the administration of EndocineTM were noted
in pre-clinical toxicology or efﬁcacy studies (unpublished data). The
two components of EndocineTM, monoolein (monoglyceride) and
oleic acid (fatty acid), are metabolites generated in mammalians
when lipids (triglycerides) are mobilized and energy needed.
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onoolein is composed of glycerol and oleic acid and is a nontoxic,
iodegradable and biocompatible material which is included in the
DA Inactive Ingredients Guide and in nonparenteral medicines
icensed in the United Kingdom [53]. Oleic acid has been described
s being the most abundant fatty acid in human adipose tissue
nd it is abundantly present in mammalian tissues including tis-
ues from rat, chicken, pig and cow [54,55]. Both oleic acid and
onoolein and are classiﬁed as GRAS (generally recognized as
afe) by the FDA, US. A study in mice showed that EndocineTM
ixed with a commercially available trivalent split inﬂuenza vac-
ine (Vaxigrip) signiﬁcantly (p < 0.003–0.05) improved the humoral
HI, VN) and cellular (IFN and IL-2 secreting cells) immunity upon
asal administration [21]. Furthermore, intranasal immunization
ith the EndocineTM formulated vaccine signiﬁcantly increased
he H1N1-speciﬁc IgA levels both in serum and nasal washings
21]. In the present study, we have shown that EndocineTM for-
ulated inactivated pH1N1/09 inﬂuenza vaccines administered as
asal drops induced a protective systemic immune response in
nﬂuenza naïve ferrets. Serum HI antibody titers of ≥40 (GMT)
ere already measured after one immunization, even at the low-
st antigen dose of 5 g HA split antigen. All animals in this
tudy received three nasal immunizations, but optimal serological
esponses were already measured after two immunizations and the
hird immunization proved to be redundant for antibody induc-
ion. EndocineTM formulated split antigen at an antigen dose of
5 g HA induced signiﬁcant higher HI and VN antibody titers than
ndocineTM formulated whole virus at the same HA antigen dose. In
eneral inactivated whole virion vaccines are more immunogenic
han split/subunit vaccines [56]. However, it has been shown that
hole virion vaccines may  be more effective without an additional
djuvant [57], and it was mentioned that the neutralizing activ-
ty of an adjuvanted whole virion H5N1 vaccine was lower than
hat of an adjuvanted split-virion H5N1 vaccine [58]. The intratra-
heal route of virus inoculation establishes a reproducible severe
neumonia in the ferret model [36]. Ferrets immunized with nasal
ndocineTM formulated vaccines, but not ferrets immunized with
arenteral TIV were protected from severe pneumonia. Protection
rom pneumonia corresponded with the absence of detectable virus
eplication in the lung and absent or signiﬁcantly reduced virus
eplication in the upper respiratory tract. Also the previously devel-
ped CT-scanning [14,15,28,29], conﬁrmed that nasal EndocineTM
ormulated vaccine, but not parenteral TIV protected the ferrets
rom severely affected and inﬂamed lungs and marked alterations
n ALVs.
Current candidate inﬂuenza vaccine design has a strong focus
n mucosal immunity and the crucial role of mucosal adjuvants
n the development of effective inactivated or subunit nasal vac-
ines [14–18]. Adjuvanted nasal vaccines may  have the advantage
o induce systemic as well as mucosal immunity, including speciﬁc
ecretory IgA (S-IgA) [6]. Locally produced antibodies, particu-
arly S-IgA have been demonstrated to play an important role in
esponses to natural infection. Pre-existing S-IgA antibodies can
revent infection by neutralizing inﬂuenza virus before it passes
he mucosal barrier, can effectively prevent infection of epithelial
ells and have been shown to contribute to the establishment of
ross-protection [59]. In the present ferret study, nasal wash and
wab samples were collected for detection of antibodies against
nﬂuenza. Interestingly, the nasal wash procedure clearly yielded
igher antibody titers than the nasal cotton swabs. EndocineTM for-
ulated split antigen (15 g HA) induced signiﬁcantly (p < 0.05)
igher nasal Ig titers in nasal wash samples after two immun-
zations compared to the parenteral vaccine (manuscript in
reparation). Furthermore, the present study showed that the
ndocineTM formulated inactivated pH1N1/09 inﬂuenza vaccines
dministered nasally induced broad speciﬁc systemic antibody
esponses in naïve ferrets. The EndocineTM formulated split antigen
[32 (2014) 3307–3315
(15 g HA) vaccine induced cross reactive HI antibody titers of
>40 (GMT) against distant viruses of swine origin already after one
immunization and both HI and VN cross reactive titers>200 (GMT)
was achieved after two immunizations.
Overall this study shows the feasibility to induce protective
systemic immunity after intranasal administration of relatively
low doses inactivated pH1N1/09 antigens when formulated with
EndocineTM. This promising data not only justiﬁes additional stud-
ies in the ferret model to deﬁne the number of immunizations
needed for protection, as well as evaluation of optimal antigen type
and dose, but also planning for further clinical studies in different
age groups, including children and the elderly.
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